{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:36:45Z","timestamp":1794379005127,"version":"4.9.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic necrotizing vasculitis comprises a group of diseases resembling polyarteritis nodosa and anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA): granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and microscopic polyangiitis. The definitive diagnosis is made in cooperation with a reference center for autoimmune diseases and rare systemic diseases or a competency center. The management goals are: to obtain remission and, in the long term, healing; to reduce the risk of relapses; to limit and reduce the sequelae linked to the disease; to limit the side effects and the sequelae linked to the treatments; to improve or at least maintain the best possible quality of life; and to maintain socio-professional integration and\/or allow a rapid return to school and\/or professional activity. Information and therapeutic education of the patients and those around them are an integral part of the care. All health professionals and patients should be informed of the existence of patient associations. The treatment of vasculitis is based on variable combinations of glucocorticoids and immunosuppressants, chosen and adapted according to the disease concerned, the severity and\/or extent of the disease, and the underlying factors (age, kidney function, etc.). Follow-up clinical and paraclinical examinations must be carried out regularly to clarify the progression of the disease, detect and manage treatment failures and possible relapses early on, and limit sequelae and complications (early then late) related to the disease or treatment. A distinction is made between the induction therapy, lasting approximately 3\u20136\u00a0months and aimed at putting the disease into remission, and the maintenance treatment, lasting 12\u201348\u00a0months, or even longer. The role of the increase or testing positive again for ANCA as a predictor of a relapse, which has long been controversial, now seems to have greater consensus: Anti-myeloperoxidase ANCAs are less often associated with a relapse of vasculitis than anti-PR3 ANCA.\n<\/jats:p>","DOI":"10.1186\/s13023-020-01621-3","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T04:02:28Z","timestamp":1609214548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)"],"prefix":"10.1186","volume":"15","author":[{"given":"Benjamin","family":"Terrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Darbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile-Audrey","family":"Durel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Papo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Puechal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Quemeneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Taille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Aumaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cathebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Daugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Diot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil El","family":"Karoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Guilpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jachiet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie Jourde","family":"Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Landron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Le Jeunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Remy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Vandergheynst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"issue":"10","key":"1621_CR1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/ard.59.10.800","volume":"59","author":"C Auzary","year":"2000","unstructured":"Auzary C, Huong DT, Wechsler B, Vauthier-Brouzes D, Piette JC. Pregnancy in patients with Wegener\u2019s granulomatosis: report of five cases in three women. Ann Rheum Dis. 2000;59(10):800\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1621_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1081-1206(10)61400-7","volume":"93","author":"PJ Bansal","year":"2004","unstructured":"Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol. 2004;93(4):398\u2013401.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"1621_CR3","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 2017;69(12):2338\u201350.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1621_CR4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/art.20082","volume":"51","author":"D Bligny","year":"2004","unstructured":"Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener\u2019s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum. 2004;51(1):83\u201391.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1621_CR5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/art.1780330803","volume":"33","author":"DA Bloch","year":"1990","unstructured":"Bloch DA, Michel BA, Hunder GG, McShane DJ, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum. 1990;33(8):1068\u201373.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1621_CR6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt X, Cohen Tervaert J-W, Arimura Y, Blockmans D, Flores-Su\u00e1rez LF, Guillevin L, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683\u201392.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1621_CR7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jbspin.2014.10.001","volume":"81","author":"K Briot","year":"2014","unstructured":"Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Jt Bone Spine Rev Rhum. 2014;81(6):493\u2013501.","journal-title":"Jt Bone Spine Rev Rhum"},{"issue":"8","key":"1621_CR8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521\u201337.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1621_CR9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.1780330808","volume":"33","author":"LH Calabrese","year":"1990","unstructured":"Calabrese LH, Michel BA, Bloch DA, Arend WP, Edworthy SM, Fauci AS, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum. 1990;33(8):1108\u201313.","journal-title":"Arthritis Rheum"},{"issue":"Suppl_2","key":"1621_CR10","doi-asserted-by":"publisher","first-page":"kez063.015","DOI":"10.1093\/rheumatology\/kez063.015","volume":"58","author":"M Casal Moura","year":"2019","unstructured":"Casal Moura M, Mira M, Massat A, Thompson G, Berti A, Baquir M, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe renal disease. Rheumatology. 2019;58(Suppl_2):kez063.015. https:\/\/doi.org\/10.1093\/rheumatology\/kez063.015.","journal-title":"Rheumatology"},{"issue":"10","key":"1621_CR11","first-page":"1317","volume":"42","author":"P Charles","year":"2013","unstructured":"Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla \u00c9, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Medicale Paris Fr 1983. 2013a;42(10):1317\u201330.","journal-title":"Presse Medicale Paris Fr 1983"},{"issue":"8","key":"1621_CR12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau \u00c9, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1621_CR13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/hrt.2006.088443","volume":"93","author":"G Chironi","year":"2007","unstructured":"Chironi G, Pagnoux C, Simon A, Pasquinelli-Balice M, Del-Pino M, Gariepy J, et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart Br Card Soc. 2007;93(1):96\u20139.","journal-title":"Heart Br Card Soc"},{"issue":"8","key":"1621_CR14","first-page":"477","volume":"52","author":"LC Chumbley","year":"1977","unstructured":"Chumbley LC, Harrison EG, DeRemee RA. Allergic granulomatosis and angiitis (Churg\u2013Strauss syndrome), Report and analysis of 30 cases. Mayo Clin Proc. 1977;52(8):477\u201384.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1621_CR15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acr.21983","volume":"65","author":"MEB Clowse","year":"2013","unstructured":"Clowse MEB, Richeson RL, Pieper C, Merkel PA. Vasculitis Clinical Research Consortium. Pregnancy outcomes among patients with vasculitis. Arthritis Care Res. 2013;65(8):1370\u20134.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"1621_CR16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen P, Pagnoux C, Mahr A, Ar\u00e8ne J-P, Mouthon L, Le Guern V, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57(4):686\u201393.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1621_CR17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.39472","volume":"68","author":"E Crickx","year":"2016","unstructured":"Crickx E, Machelart I, Lazaro E, Kahn J-E, Cohen-Aubart F, Martin T, et al. Intravenous Immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68(3):702\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1621_CR18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10157-012-0735-y","volume":"17","author":"E Csernok","year":"2013","unstructured":"Csernok E. ANCA testing: the current stage and perspectives. Clin Exp Nephrol. 2013;17(5):615\u20138.","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"1621_CR19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/rheumatology\/keh028","volume":"43","author":"E Csernok","year":"2004","unstructured":"Csernok E, Holle J, Hellmich B, Willem J, Tervaert C, Kallenberg CGM, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener\u2019s granulomatosis: first results from a multicentre study. Rheumatology. 2004;43(2):174\u201380.","journal-title":"Rheumatology"},{"key":"1621_CR20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","volume":"42","author":"P Charles","year":"2013","unstructured":"Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla \u00c9, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med. 2013b;42:1317\u201330.","journal-title":"Presse Med"},{"issue":"3","key":"1621_CR21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1378\/chest.113.3.836","volume":"113","author":"ES Dayoan","year":"1998","unstructured":"Dayoan ES, Dimen LL, Boylen CT. Successful treatment of Wegener\u2019s granulomatosis during pregnancy: a case report and review of the medical literature. Chest. 1998;113(3):836\u20138.","journal-title":"Chest"},{"issue":"12","key":"1621_CR22","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.1780391215","volume":"39","author":"K De Groot","year":"1996","unstructured":"De Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, N\u00f6lle B, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener\u2019s granulomatosis. Methotrexate versus trimethoprim\/sulfamethoxazole. Arthritis Rheum. 1996;39(12):2052\u201361.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1621_CR23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K De Groot","year":"2009","unstructured":"De Groot K, Harper L, Jayne DRW, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670\u201380.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1621_CR24","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, Tervaert JWC, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1 Suppl 64","key":"1621_CR25","first-page":"S63","volume":"29","author":"M De Menthon","year":"2011","unstructured":"De Menthon M, Cohen P, Pagnoux C, Buchler M, Sibilia J, D\u00e9tr\u00e9e F, et al. Infliximab or rituximab for refractory Wegener\u2019s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S63-71.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1621_CR26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1086\/520433","volume":"29","author":"WM El-Sadr","year":"1999","unstructured":"El-Sadr WM, Luskin-Hawk R, Yurik TM, Walker J, Abrams D, John SL, et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis. 1999;29(4):775\u201383.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1621_CR27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371\u201380.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1621_CR28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"AS Fauci","year":"1983","unstructured":"Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76\u201385.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1621_CR29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","volume":"301","author":"AS Fauci","year":"1979","unstructured":"Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301(5):235\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"1621_CR30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1621_CR31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.1780330812","volume":"33","author":"JF Fries","year":"1990","unstructured":"Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summ Arthritis Rheum. 1990;33(8):1135\u20136.","journal-title":"Summ Arthritis Rheum"},{"issue":"1","key":"1621_CR32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/ajkd.2002.29876","volume":"39","author":"H Gallagher","year":"2002","unstructured":"Gallagher H, Kwan JTC, Jayne DRW. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis. 2002;39(1):42\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"1621_CR33","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/rheumatology\/36.12.1290","volume":"36","author":"M Gayraud","year":"1997","unstructured":"Gayraud M, Guillevin L, Cohen P, Lhote F, Cacoub P, Deblois P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for vasculitides. Br J Rheumatol. 1997;36(12):1290\u20137.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"1621_CR34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","volume":"44","author":"M Gayraud","year":"2001","unstructured":"Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44(3):666\u201375.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1621_CR35","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1681\/ASN.2014010046","volume":"26","author":"D Geetha","year":"2015","unstructured":"Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976\u201385.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1621_CR36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/rheumatology\/33.10.959","volume":"33","author":"T G\u00e9n\u00e9reau","year":"1994","unstructured":"G\u00e9n\u00e9reau T, Lortholary O, Leclerq P, Grenet D, Tub\u00e9ry M, Sicard D, et al. Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol. 1994;33(10):959\u201362.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"1621_CR37","first-page":"198","volume":"148","author":"L Guillevin","year":"1997","unstructured":"Guillevin L, Cevallos R, Durand-Gasselin B, Lhote F, Jarrousse B, Callard P. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris). 1997;148(3):198\u2013204.","journal-title":"Ann Med Interne (Paris)"},{"issue":"1","key":"1621_CR38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","volume":"78","author":"L Guillevin","year":"1999","unstructured":"Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26\u201337.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"1621_CR39","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener\u2019s granulomatosis. Arthritis Rheum. 1997;40(12):2187\u201398.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1621_CR40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","volume":"42","author":"L Guillevin","year":"1999","unstructured":"Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421\u201330.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1621_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF02714432","volume":"165","author":"L Guillevin","year":"1987","unstructured":"Guillevin L, Guittard T, Bletry O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 1987;165(3):165\u201372.","journal-title":"Lung"},{"issue":"5","key":"1621_CR42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00005792-199509000-00002","volume":"74","author":"L Guillevin","year":"1995","unstructured":"Guillevin L, Lhote F, Cohen P, Sauvaget F, Jarrousse B, Lortholary O, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore). 1995;74(5):238\u201353.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"1621_CR43","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.1780381116","volume":"38","author":"L Guillevin","year":"1995","unstructured":"Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, G\u00e9n\u00e9reau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg\u2013Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638\u201345.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1621_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17\u201328.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1621_CR45","first-page":"405","volume":"143","author":"L Guillevin","year":"1992","unstructured":"Guillevin L, Lhote F, Jarrousse B, Fain O. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris). 1992;143(6):405\u201316.","journal-title":"Ann Med Interne (Paris)"},{"issue":"2","key":"1621_CR46","first-page":"289","volume":"20","author":"L Guillevin","year":"1993","unstructured":"Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. 1993;20(2):289\u201398.","journal-title":"J Rheumatol"},{"issue":"5","key":"1621_CR47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/ard.53.5.334","volume":"53","author":"L Guillevin","year":"1994","unstructured":"Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis. 1994;53(5):334\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1621_CR48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.20401","volume":"51","author":"L Guillevin","year":"2004","unstructured":"Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. 2004;51(3):482\u20137.","journal-title":"Arthritis Rheum"},{"key":"1621_CR49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0463.1990.tb05737.x","volume":"19","author":"L Guillevin","year":"1990","unstructured":"Guillevin L, Rosser J, Cacoub P, Mousson C, Jarrousee B. Methylprednisolone in the treatment of Wegener\u2019s granulomatosis, polyarteritis nodosa and Churg-Strauss angiitis. APMIS Suppl. 1990;19:52\u20133.","journal-title":"APMIS Suppl"},{"issue":"1","key":"1621_CR50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","volume":"49","author":"L Guillevin","year":"2003","unstructured":"Guillevin L, Cohen P, Mahr A, Ar\u00e8ne J-P, Mouthon L, Pu\u00e9chal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49(1):93\u2013100.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1621_CR51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.md.0000180792.80212.5e","volume":"84","author":"L Guillevin","year":"2005","unstructured":"Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84(5):313\u201322.","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"1621_CR52","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380.","journal-title":"N Engl J Med"},{"issue":"1","key":"1621_CR53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19\u201327.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1621_CR54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, Perrodeau \u00c9, Samson M, Bonnotte B, N\u00e9el A, Agard C, et al. Long-term rituximab use to maintain remission of ANCA-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173(3):179\u201387.","journal-title":"Ann Intern Med."},{"issue":"2","key":"1621_CR55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","volume":"33","author":"F Han","year":"2011","unstructured":"Han F, Liu G, Zhang X, Li X, He Q, He X, et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol. 2011;33(2):185\u201392.","journal-title":"Am J Nephrol"},{"issue":"7","key":"1621_CR56","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/ndt\/14.7.1789","volume":"14","author":"MA Harber","year":"1999","unstructured":"Harber MA, Tso A, Taheri S, Tuck SM, Burns A. Wegener\u2019s granulomatosis in pregnancy\u2013the therapeutic dilemma. Nephrol Dial Transplant. 1999;14(7):1789\u201391.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1621_CR57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","volume":"71","author":"L Harper","year":"2012","unstructured":"Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1621_CR58","first-page":"19","volume":"49","author":"M Haubitz","year":"1998","unstructured":"Haubitz M, Ehlerding C, Kamino K, Koch KM, Brunkhorst R. Reduced gonadal toxicity after i.v. cyclophosphamide administration in patients with nonmalignant diseases. Clin Nephrol. 1998;49(1):19\u201323.","journal-title":"Clin Nephrol"},{"issue":"10","key":"1621_CR59","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","volume":"41","author":"M Haubitz","year":"1998","unstructured":"Haubitz M, Schellong S, G\u00f6bel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41(10):1835\u201344.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1621_CR60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1621_CR61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/14656566.5.1.25","volume":"5","author":"B Hellmich","year":"2004","unstructured":"Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother. 2004;5(1):25\u201335.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1621_CR62","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/art.23470","volume":"58","author":"C Henegar","year":"2008","unstructured":"Henegar C, Pagnoux C, Pu\u00e9chal X, Zucker J-D, Bar-Hen A, Le Guern V, et al. A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum. 2008;58(5):1528\u201338.","journal-title":"Arthritis Rheum"},{"issue":"21","key":"1621_CR63","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381\u20138.","journal-title":"JAMA"},{"issue":"6","key":"1621_CR64","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488\u201398.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1621_CR65","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/art.1780351113","volume":"35","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener\u2019s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35(11):1322\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1621_CR66","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/ard.2010.130203","volume":"69","author":"JU Holle","year":"2010","unstructured":"Holle JU, Gross WL, Holl-Ulrich K, Ambrosch P, Noelle B, Both M, et al. Prospective long-term follow-up of patients with localised Wegener\u2019s granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis. 2010;69(11):1934\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1621_CR67","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle JU, Gross WL, Latza U, N\u00f6lle B, Ambrosch P, Heller M, et al. Improved outcome in 445 patients with Wegener\u2019s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257\u201366.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1621_CR68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","volume":"23","author":"W Hu","year":"2008","unstructured":"Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23(4):1307\u201312.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"1621_CR69","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introd Arthritis Rheum. 1990;33(8):1065\u20137.","journal-title":"Introd Arthritis Rheum"},{"issue":"12","key":"1621_CR70","first-page":"2571","volume":"29","author":"DL Huong","year":"2002","unstructured":"Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29(12):2571\u20136.","journal-title":"J Rheumatol"},{"key":"1621_CR71","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/978-1-4757-9182-2_84","volume":"336","author":"DR Jayne","year":"1993","unstructured":"Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol. 1993;336:469\u201372.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1621_CR72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.berh.2004.11.004","volume":"19","author":"D Jayne","year":"2005","unstructured":"Jayne D. How to induce remission in primary systemic vasculitis. Best Pract Res Clin Rheumatol. 2005;19(2):293\u2013305.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl 2","key":"1621_CR73","first-page":"SII110","volume":"69","author":"DRW Jayne","year":"2002","unstructured":"Jayne DRW. Conventional treatment and outcome of Wegener\u2019s granulomatosis and microscopic polyangiitis. Cleve Clin J Med. 2002;69(Suppl 2):SII110-115.","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"1621_CR74","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1621_CR75","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadonien\u00e9 J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"1621_CR76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187\u201392.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1621_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1621_CR78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399\u2013405.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1621_CR79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"1621_CR80","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras A, Pagnoux C, Haubitz M, de Groot K, Puechal X, Tervaert JWC, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1621_CR81","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336\u201343.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1621_CR82","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","volume":"42","author":"PJ Klemmer","year":"2003","unstructured":"Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42(6):1149\u201353.","journal-title":"Am J Kidney Dis"},{"issue":"1 Suppl 70","key":"1621_CR83","first-page":"S77","volume":"30","author":"A Kostianovsky","year":"2012","unstructured":"Kostianovsky A, Hauser T, Pagnoux C, Cohen P, Daugas E, Mouthon L, et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients\u2019 features and prognostic factors. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S77-82.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"1621_CR84","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1621_CR85","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0035-3787(04)70894-2","volume":"160","author":"P Lafor\u00eat","year":"2004","unstructured":"Lafor\u00eat P, Eymard B. Exercise-intolerance and exercise-induced rhabdomyolisis: etiology and diagnosis. Rev Neurol (Paris). 2004;160(2):217\u201323.","journal-title":"Rev Neurol (Paris)"},{"issue":"4","key":"1621_CR86","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11926-005-0036-5","volume":"7","author":"SE Lane","year":"2005","unstructured":"Lane SE, Watts R, Scott DGI. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7(4):270\u20135.","journal-title":"Curr Rheumatol Rep"},{"issue":"6 Suppl 36","key":"1621_CR87","first-page":"S3","volume":"22","author":"CA Langford","year":"2004","unstructured":"Langford CA. Antineutrophil cytoplasmic antibodies should not be used to guide treatment in Wegener\u2019s granulomatosis. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S3-6.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1621_CR88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.7326\/0003-4819-129-1-199807010-00012","volume":"129","author":"CA Langford","year":"1998","unstructured":"Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med. 1998;129(1):49\u201358.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1621_CR89","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E","volume":"42","author":"CA Langford","year":"1999","unstructured":"Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener\u2019s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999;42(12):2666\u201373.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1621_CR90","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","volume":"73","author":"CA Langford","year":"2014","unstructured":"Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s). Ann Rheum Dis. 2014;73(7):1376\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1621_CR91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9343(03)00077-9","volume":"114","author":"CA Langford","year":"2003","unstructured":"Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener\u2019s granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114(6):463\u20139.","journal-title":"Am J Med"},{"issue":"2","key":"1621_CR92","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/art.20240","volume":"51","author":"CA Langford","year":"2004","unstructured":"Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener\u2019s granulomatosis. Arthritis Rheum. 2004;51(2):278\u201383.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1621_CR93","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.30296","volume":"63","author":"G Le Guenno","year":"2011","unstructured":"Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L, French Vasculitis Study Group. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011;63(5):1435\u201345.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1621_CR94","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","volume":"33","author":"RY Leavitt","year":"1990","unstructured":"Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis. Arthritis Rheum. 1990;33(8):1101\u20137.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1621_CR95","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0002-9343(79)90634-X","volume":"67","author":"ES Leib","year":"1979","unstructured":"Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med. 1979;67(6):941\u20137.","journal-title":"Am J Med"},{"issue":"8","key":"1621_CR96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/art.1780330805","volume":"33","author":"RW Lightfoot","year":"1990","unstructured":"Lightfoot RW, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33(8):1088\u201393.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1621_CR97","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/1529-0131(199707)40:7<1354::AID-ART22>3.0.CO;2-M","volume":"40","author":"P Luisiri","year":"1997","unstructured":"Luisiri P, Lance NJ, Curran JJ. Wegener\u2019s granulomatosis in pregnancy. Arthritis Rheum. 1997;40(7):1354\u201360.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1621_CR98","first-page":"671","volume":"87","author":"RA Luqmani","year":"1994","unstructured":"Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671\u20138.","journal-title":"QJM"},{"issue":"2","key":"1621_CR99","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.berh.2004.11.002","volume":"19","author":"RA Luqmani","year":"2005","unstructured":"Luqmani RA, Pathare S, Kwok-Fai TL. How to diagnose and treat secondary forms of vasculitis. Best Pract Res Clin Rheumatol. 2005;19(2):321\u201336.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"1621_CR100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DRW, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"1621_CR101","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/art.20077","volume":"51","author":"A Mahr","year":"2004","unstructured":"Mahr A, Guillevin L, Poissonnet M, Aym\u00e9 S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener\u2019s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92\u20139.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1621_CR102","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","volume":"58","author":"V Martinez","year":"2008","unstructured":"Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58(1):308\u201317.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1621_CR103","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094\u2013100.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1621_CR104","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1172\/JCI78182","volume":"125","author":"A Millet","year":"2015","unstructured":"Millet A, Martin KR, Bonnefoy F, Saas P, Mocek J, Alkan M, et al. Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. J Clin Investig. 2015;125(11):4107\u201321.","journal-title":"J Clin Investig"},{"issue":"9","key":"1621_CR105","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","volume":"65","author":"EM Miloslavsky","year":"2013","unstructured":"Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65(9):2441\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1621_CR106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341\u20133.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1621_CR107","first-page":"1763","volume":"31","author":"VM Ognenovski","year":"2004","unstructured":"Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004;31(9):1763\u20137.","journal-title":"J Rheumatol"},{"issue":"5","key":"1621_CR108","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/keq421","volume":"50","author":"C Pagnoux","year":"2011","unstructured":"Pagnoux C, Le Guern V, Goffinet F, Diot E, Limal N, Pannier E, et al. Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. Rheumatology. 2011;50(5):953\u201361.","journal-title":"Rheumatology"},{"issue":"26","key":"1621_CR109","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa J-J, Ruivard M, Ducroix J-P, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790\u2013803.","journal-title":"N Engl J Med"},{"issue":"4","key":"1621_CR110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux C, Qu\u00e9m\u00e9neur T, Ninet J, Diot E, Kyndt X, de Wazi\u00e8res B, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117\u201327.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1621_CR111","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.27240","volume":"62","author":"C Pagnoux","year":"2010","unstructured":"Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616\u201326.","journal-title":"Arthritis Rheum"},{"key":"1621_CR112","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","volume":"76","author":"JK Park","year":"2017","unstructured":"Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76:1559\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1621_CR113","first-page":"1153","volume":"21","author":"R Pauzner","year":"1994","unstructured":"Pauzner R, Mayan H, Hershko E, Alcalay M, Farfel Z. Exacerbation of Wegener\u2019s granulomatosis during pregnancy: report of a case with tracheal stenosis and literature review. J Rheumatol. 1994;21(6):1153\u20136.","journal-title":"J Rheumatol"},{"issue":"9140","key":"1621_CR114","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0140-6736(05)61046-X","volume":"352","author":"R Priori","year":"1998","unstructured":"Priori R, Tomassini M, Magrini L, Conti F, Valesini G. Churg-Strauss syndrome during pregnancy after steroid withdrawal. Lancet. 1998;352(9140):1599\u2013600.","journal-title":"Lancet"},{"issue":"11","key":"1621_CR115","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Pu\u00e9chal","year":"2017","unstructured":"Pu\u00e9chal X, Pagnoux C, Baron G, Qu\u00e9meneur T, N\u00e9el A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69(11):2175\u201386.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1621_CR116","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","volume":"58","author":"X Pu\u00e9chal","year":"2019","unstructured":"Pu\u00e9chal X, Pagnoux C, Baron G, Lifermann F, Geffray L, Qu\u00e9meneur T, et al. Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology. 2019;58(12):2107\u201316.","journal-title":"Rheumatology"},{"issue":"3","key":"1621_CR117","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.39450","volume":"68","author":"X Pu\u00e9chal","year":"2016","unstructured":"Pu\u00e9chal X, Pagnoux C, Perrodeau \u00c9, Hamidou M, Boffa J-J, Kyndt X, et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener\u2019s) or microscopic polyangiitis. Arthritis Rheumatol. 2016;68(3):690\u2013701.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1621_CR118","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi C, Cohen P, Pagnoux C, Mahr A, Ar\u00e8ne J-P, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586\u201394.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1621_CR119","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","volume":"62","author":"C Ribi","year":"2010","unstructured":"Ribi C, Cohen P, Pagnoux C, Mahr A, Ar\u00e8ne J-P, Pu\u00e9chal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62(4):1186\u201397.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1621_CR120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/CMR.17.4.770-782.2004","volume":"17","author":"M Rodriguez","year":"2004","unstructured":"Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004;17(4):770\u201382.","journal-title":"Clin Microbiol Rev"},{"key":"1621_CR121","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","volume":"43","author":"M Samson","year":"2013","unstructured":"Samson M, Pu\u00e9chal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60\u20139.","journal-title":"J Autoimmun"},{"issue":"2","key":"1621_CR122","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.autrev.2013.10.001","volume":"13","author":"M Samson","year":"2014","unstructured":"Samson M, Pu\u00e9chal X, Devilliers H, Ribi C, Cohen P, Bienvenu B, et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev. 2014;13(2):197\u2013205.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1621_CR123","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"1621_CR124","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335(1):16\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1621_CR125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","volume":"120","author":"CA Stegeman","year":"1994","unstructured":"Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120(1):12\u20137.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1621_CR126","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44(4):912\u201320.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1621_CR127","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"1621_CR128","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","volume":"48","author":"JH Stone","year":"2003","unstructured":"Stone JH, Wegener\u2019s Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener\u2019s granulomatosis: baseline data on patients in the Wegener\u2019s granulomatosis etanercept trial. Arthritis Rheum. 2003;48(8):2299\u2013309.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1621_CR129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2169\/internalmedicine.46.6070","volume":"46","author":"T Sugimoto","year":"2007","unstructured":"Sugimoto T, Deji N, Kume S, Osawa N, Sakaguchi M, Isshiki K, et al. Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener\u2019s granulomatosis effectively treated with early plasma exchange therapy. Intern Med. 2007;46(1):49\u201353.","journal-title":"Intern Med"},{"issue":"4","key":"1621_CR130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.20433","volume":"63","author":"R Suppiah","year":"2011","unstructured":"Suppiah R, Judge A, Batra R, Flossmann O, Harper L, H\u00f6glund P, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener\u2019s granulomatosis and microscopic polyangiitis. Arthritis Care Res. 2011;63(4):588\u201396.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"1621_CR131","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3899\/jrheum.130882","volume":"41","author":"B Terrier","year":"2014","unstructured":"Terrier B, Chironi G, Pagnoux C, Cohen P, Pu\u00e9chal X, Simon A, et al. Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides: results of a longterm followup study. J Rheumatol. 2014;41(4):723\u20139.","journal-title":"J Rheumatol"},{"issue":"8","key":"1621_CR132","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier B, Pagnoux C, Perrodeau \u00c9, Karras A, Khouatra C, Auma\u00eetre O, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1621_CR133","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE Van Daalen","year":"2017","unstructured":"Van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(6):1064\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1621_CR134","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","volume":"84","author":"M Walsh","year":"2013","unstructured":"Walsh M, Casian A, Flossmann O, Westman K, H\u00f6glund P, Pusey C, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84(2):397\u2013402.","journal-title":"Kidney Int"},{"key":"1621_CR135","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, Szpirt WM, Pu\u00e9chal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1621_CR136","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/ard.60.2.170","volume":"60","author":"RA Watts","year":"2001","unstructured":"Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis. 2001;60(2):170\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1621_CR137","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/ard.60.12.1156a","volume":"60","author":"RA Watts","year":"2001","unstructured":"Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60(12):1156\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1621_CR138","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1378\/chest.117.3.708","volume":"117","author":"ME Wechsler","year":"2000","unstructured":"Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, Haranath SP, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708\u201313.","journal-title":"Chest"},{"issue":"20","key":"1621_CR139","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"1621_CR140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med. 2005;352(4):351\u201361.","journal-title":"N Engl J Med"},{"issue":"4","key":"1621_CR141","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jca.20035","volume":"20","author":"K Yamagata","year":"2005","unstructured":"Yamagata K, Hirayama K, Mase K, Yamaguchi N, Kobayashi M, Takahashi H, et al. Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN. J Clin Apheresis. 2005;20(4):244\u201351.","journal-title":"J Clin Apheresis"},{"issue":"13","key":"1621_CR142","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jama.1996.03540130018007","volume":"276","author":"Centers for Disease Control and Prevention","year":"1996","unstructured":"Centers for Disease Control and Prevention. Pneumocystis pneumonia\u2013Los Angeles, 1981. JAMA. 1996;276(13):1020\u20132.","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1186\/s13023-021-01787-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01621-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T11:15:05Z","timestamp":1627643705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01621-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":142,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01621-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13023-021-01787-4","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"29 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-021-01787-4","URL":"https:\/\/doi.org\/10.1186\/s13023-021-01787-4","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BT reports consulting fees from Roche, AstraZeneca, and Roche-Chugai; speaking fees from Grifols. RD reports no conflicts of interest. CD reports no conflicts of interest. EH reports consulting fees from Actelion, Boehringer Ingelheim, Bayer, GSK, Roche-Chugai, Sanofi-Genzyme; speaking fees from Actelion, GSK, Roche-Chugai; and research funding from Octapharma, CSL Behring, GSK, Roche-Chugai, and Actelion. AK reports speaking fees from Roche. HM reports consulting fees from Amicus Therapeutics, Shire; speaking fees from Sanofi-Genzyme, Amicus Therapeutics. TP reports speaking fees from GSK, Ferring. XP has been an investigator in academic studies for which rituximab was provided by Roche Pharma; has declared speaking fees and honoraria (Boehringer Ingelheim, Sanofi, Pfizer, LFB), and congress inscription\/travel\/accommodation (Sanofi). GP reports no conflicts of interest. TQ reports research funding from Chemocentryx. MS reports consulting fees from Roche-Chugai; speaking fees from Roche-Chugai. CT reports consulting fees from Sanofi, GSK, Novartis, AstraZeneca; speaking fees from GSK, Sanofi, AstraZeneca; and research funding from GSK. LG reports consulting fees from Janssen, Lilly Pharma, AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"351"}}